ACTU vs ADIL

Actuate Therapeutics, Inc. vs Adial Pharmaceuticals, Inc — Valuation Comparison 2026

ACTU

Biotechnology
Actuate Therapeutics, Inc.
Quality
3.7
out of 10
Value Trap
12
SAFE
Price
$2.08
Last close
Models
7/13
Active
VS

ADIL

Biotechnology
Adial Pharmaceuticals, Inc
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$2.53
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ACTU Fair ValueACTU Upside ADIL Fair ValueADIL Upside
Bayesian DCF Intrinsic $0.74 -64.6% $1.85 -27.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.04 -98.6% $0.33 -78.5%
Dynamic NAV Asset-Based $0.85 -59.2% $1.58 -37.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ACTU vs ADIL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ACTU vs ADIL — Which Stock Is More Undervalued?

ADIL scores higher with a 4.4/10 quality rating vs ACTU's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Actuate Therapeutics, Inc. (ACTU) and Adial Pharmaceuticals, Inc (ADIL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ACTU currently trades at $2.08 with a QOC of 3.7/10, while ADIL trades at $2.53 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).